In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi U.S. strategy exec

Executive Summary

Sanofi-Aventis names Juergen Lasowski, PhD, to head U.S. business development & strategy. He formerly served as Aventis VP-strategic planning & business and head of strategic development at predecessor company Hoechst Marion Roussel. Lasowski will report to Tim Rothwell, who became Sanofi-Aventis U.S. president following the completion of the merger (1"The Pink Sheet" June 28, 2004, p. 19)...

You may also be interested in...



Aventis U.S. Team Has RPR Execs Heading Commercial Op & Finance

Rhone-Poulenc Rorer Senior VP and General Manager John Leone is heading Aventis' North American Pharmaceuticals commercial operations - sales and marketing.

QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.

Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.

UsernamePublicRestriction

Register

PS044983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel